Altimmune Advances Pemvidutide Trials with Phase 3 Initiation and Positive AUD Data
Event summary
- Altimmune initiated the global PERFORMA Phase 3 trial for pemvidutide in MASH, with data readout anticipated in 2029.
- Positive topline data from the RECLAIM Phase 2 trial showed statistically significant reduction in heavy drinking days for AUD patients.
- Completed patient enrollment in the RESTORE Phase 2 trial for ALD, with topline data expected in the second half of 2027.
- $519 million in cash, cash equivalents, and investments as of June 30, 2026.
The big picture
Altimmune is positioning itself as a key player in the treatment of serious liver diseases with its lead candidate, pemvidutide. The initiation of the Phase 3 trial for MASH and positive data from the AUD trial highlight the company's strategic focus on addressing unmet medical needs. The biopharmaceutical industry continues to see significant investment in late-stage clinical trials, particularly for therapies targeting liver diseases and addiction disorders.
What we're watching
- Regulatory Pathway
- Whether the FDA's Fast Track and Breakthrough Therapy designations will accelerate pemvidutide's approval process for MASH and AUD.
- Clinical Execution
- The pace at which Altimmune can deliver positive data from the PERFORMA Phase 3 trial and RESTORE Phase 2 trial, critical for future commercialization.
- Financial Sustainability
- How long Altimmune's current cash position of $519 million will support its operations until potential revenue generation from pemvidutide.